Xponance Inc. Has $3.19 Million Stock Holdings in Natera, Inc. (NASDAQ:NTRA)

Xponance Inc. grew its holdings in Natera, Inc. (NASDAQ:NTRA - Free Report) by 41.3% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 22,562 shares of the medical research company's stock after buying an additional 6,591 shares during the quarter. Xponance Inc.'s holdings in Natera were worth $3,190,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in NTRA. Steward Partners Investment Advisory LLC increased its stake in shares of Natera by 1,328.0% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 357 shares of the medical research company's stock valued at $57,000 after buying an additional 332 shares in the last quarter. PNC Financial Services Group Inc. increased its position in Natera by 6.7% in the fourth quarter. PNC Financial Services Group Inc. now owns 2,951 shares of the medical research company's stock worth $467,000 after purchasing an additional 186 shares during the period. Daiwa Securities Group Inc. increased its position in Natera by 18.8% in the fourth quarter. Daiwa Securities Group Inc. now owns 2,170 shares of the medical research company's stock worth $344,000 after purchasing an additional 344 shares during the period. HighTower Advisors LLC increased its position in Natera by 9.9% in the fourth quarter. HighTower Advisors LLC now owns 11,342 shares of the medical research company's stock worth $1,795,000 after purchasing an additional 1,023 shares during the period. Finally, EverSource Wealth Advisors LLC increased its position in Natera by 372.9% in the fourth quarter. EverSource Wealth Advisors LLC now owns 331 shares of the medical research company's stock worth $52,000 after purchasing an additional 261 shares during the period. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts recently commented on the company. Wall Street Zen lowered Natera from a "hold" rating to a "sell" rating in a research report on Saturday, May 17th. Barclays lifted their price objective on Natera from $160.00 to $190.00 and gave the stock an "overweight" rating in a research report on Friday, May 9th. Piper Sandler boosted their target price on Natera from $205.00 to $210.00 and gave the stock an "overweight" rating in a research report on Thursday, May 15th. Finally, UBS Group boosted their target price on Natera from $211.00 to $218.00 and gave the stock a "buy" rating in a research report on Friday, May 9th. One analyst has rated the stock with a sell rating and fifteen have assigned a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $184.63.

Natera Price Performance

NASDAQ:NTRA opened at $160.43 on Monday. Natera, Inc. has a fifty-two week low of $92.14 and a fifty-two week high of $183.00. The stock has a market capitalization of $21.91 billion, a PE ratio of -109.14 and a beta of 1.73. The business's 50-day simple moving average is $161.05 and its 200-day simple moving average is $158.41.

Natera (NASDAQ:NTRA - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The medical research company reported ($0.50) earnings per share for the quarter, beating the consensus estimate of ($0.59) by $0.09. Natera had a negative return on equity of 18.29% and a negative net margin of 10.36%. The business had revenue of $501.83 million for the quarter, compared to analysts' expectations of $446.68 million. During the same quarter in the previous year, the business posted ($0.56) EPS. Natera's revenue for the quarter was up 36.5% on a year-over-year basis. On average, research analysts expect that Natera, Inc. will post -1.49 earnings per share for the current year.

Insider Transactions at Natera

In other Natera news, CFO Michael Burkes Brophy sold 2,018 shares of the business's stock in a transaction that occurred on Monday, April 28th. The stock was sold at an average price of $152.18, for a total value of $307,099.24. Following the sale, the chief financial officer owned 73,539 shares in the company, valued at approximately $11,191,165.02. The trade was a 2.67% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Gail Boxer Marcus sold 4,299 shares of the business's stock in a transaction that occurred on Tuesday, July 1st. The shares were sold at an average price of $167.36, for a total value of $719,480.64. Following the completion of the sale, the director owned 8,118 shares in the company, valued at $1,358,628.48. The trade was a 34.62% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 53,272 shares of company stock worth $8,345,368. 7.60% of the stock is currently owned by insiders.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera, Inc. (NASDAQ:NTRA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.